Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022		Sep. 30, 2023	Sep. 30, 2022
Total revenue		$ 55,430	$ 66,398	[1]	$ 216,700	$ 379,421	[1]
Costs and operating expenses:
Research and development		156,662	261,460	[1]	463,583	875,095	[1]
General and administrative		82,028	435,221	[1]	295,802	1,308,416	[1]
Operating Lease, Impairment Loss		96,210	0		96,210	0
Total operating expenses		341,823	721,336	[1]	902,989	2,357,509	[1]
Loss from operations		(286,393)	(654,938)	[1],[2]	(686,289)	(1,978,088)	[1],[2]
Other (expense) income:
Interest income, net		15,020	6,380	[1]	43,914	8,821	[1]
Loss on equity method investments		0	(22,711)	[1]	(1,516)	(53,764)	[1]
Loss on investments		(36,324)	(1,758)	[1]	(44,815)	(39,981)	[1]
Change in fair value of warrant liabilities		1,891	(12,445)	[1]	(1,387)	96,099	[1],[3]
Gain on deconsolidation of subsidiaries		0	15,989	[1]	0	31,889	[1],[3]
Other income (expense), net		2,893	(676)	[1]	9,045	1,473	[1]
Total other (expense) income, net		(16,520)	(15,221)	[1]	5,241	44,537	[1]
Loss before income taxes		(302,913)	(670,159)	[1]	(681,048)	(1,933,551)	[1]
Income tax (benefit) provision		(22)	(28)	[1]	127	(257)	[1]
Net Loss		(302,891)	(670,131)	[1]	(681,175)	(1,933,294)	[1],[3]
Loss attributable to non-controlling interest		0	0	[1]	0	(3,833)	[1]
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders		$ (302,891)	$ (670,131)	[1]	$ (681,175)	$ (1,929,461)	[1]
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic (in dollars per share)		$ (0.16)	$ (0.41)	[1]	$ (0.35)	$ (1.19)	[1]
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, diluted (in dollars per share)		$ (0.16)	$ (0.41)	[1]	$ (0.35)	$ (1.19)	[1]
Weighted average common shares outstanding, basic (in shares)		1,950,814	1,630,911	[1]	1,933,202	1,619,790	[1]
Weighted average common shares outstanding, diluted (in shares)		1,950,814	1,630,911	[1]	1,933,202	1,619,790	[1]
Comprehensive loss:
Net loss		$ (302,891)	$ (670,131)	[1]	$ (681,175)	$ (1,933,294)	[1],[3]
Other comprehensive loss:
Foreign currency translation adjustment		(1,599)	(2,414)	[1]	(267)	(6,195)	[1]
Total other comprehensive loss		(1,599)	(2,414)	[1]	(267)	(6,195)	[1]
Comprehensive loss		(304,490)	(672,545)	[1]	(681,442)	(1,939,489)	[1]
Cell Engineering
Total revenue	[4]	37,176	24,679	[1]	116,555	90,409	[1]
Product
Total revenue		6,495	5,190	[1]	28,949	23,024	[1]
Costs and operating expenses:
Cost of Biosecurity revenue		906	2,660	[1]	7,481	13,199	[1]
Service
Total revenue		11,759	36,529	[1]	71,196	265,988	[1]
Costs and operating expenses:
Cost of Biosecurity revenue		$ 6,017	$ 21,995	[1]	$ 39,913	$ 160,799	[1]

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

[2] As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

[3] As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

[4] Includes related party revenue of $8,727 and $10,032 for the three months ended September 30, 2023 and 2022, respectively, and $19,912 and $31,557 for the nine months ended September 30, 2023 and 2022, respectively.